SCHEMBL21568374

SCHEMBL21568374

N#Cc1cc(NC(=O)Nc2nc3ccc(Cl)nc3s2)ccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BLM P54132 4/20 0.54
▸ WRN Q14191 3/20 0.54
▸ GRM4 Q14833 1/20 0.46
▸ P2RY1 P47900 3/20 0.43
▸ HSD17B10 Q99714 7/20 0.43
▸ KDM4E B2RXH2 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ CXCR2 P25025 1/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23256590 0.92 KCNQ3 (0.46) BLMWRNP2RY1HSD17B10KDM4E
SCHEMBL21568272 0.90 BLM (0.47) BLMWRNHSD17B10KDM4ERECQL
SCHEMBL21568276 0.89 BLM (0.56) BLMWRNGRM4P2RY1HSD17B10
SCHEMBL21568229 0.88 BLM (0.54) BLMWRNGRM4P2RY1HSD17B10
SCHEMBL21568757 0.87 BLM (0.56) BLMWRNP2RY1HSD17B10MEN1
SCHEMBL23256633 0.85 P2RY1 (0.45) BLMWRNP2RY1MEN1KMT2A
SCHEMBL21568110 0.85 CXCR2 (0.43) P2RY1HSD17B10KDM4ERECQLCXCR2
SCHEMBL23256591 0.85 BLM (0.56) BLMHSD17B10
SCHEMBL21568250 0.84 BLM (0.55) BLMWRNHSD17B10KDM4ERECQL
SCHEMBL21568373 0.83 BLM (0.57) BLMWRNGRM4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2021-04-22 — — US disclosed
WO-2019217509-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 BLM 619/4885WRN 1572/4885GRM4 3199/4885
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER VHL, TP53, NUDT1 BLM 692/4885WRN 1892/4885GRM4 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback